Short interfering RNA in colorectal cancer: is it wise to shoot the messenger?

This study focuses on many innovative siRNA therapies and methodologies for delivering siRNA therapeutics to the malignant site safely and effectively for the treatment of CRC. Treatment of CRC using siRNA-associated nanoparticles (NPs) may inhibit the activity of oncogenes and MDR-related genes by targeting a range of signaling mechanisms. This study summarizes several siRNAs targeting signaling molecules, as well as the therapeutic approaches that might be employed to treat CRC in the future.PMID:37011722 | DOI:10.1016/j.ejphar.2023.175699

Source: European Journal of Pharmacology - April 3, 2023 Category: Drugs & Pharmacology Authors: Kiruthiga Chandramohan Devasahayam Jaya Balan Kasi Pandima Devi Seyed Fazel Nabavi Sara Reshadat Maryam Khayatkashani Sepideh Mahmoodifar Rosanna Filosa Nilofar Amirkhalili Soroush Pishvaei Omolbanin Sargazi Aval Seyed Mohammad Nabavi Source Type: research